SNCA and Parkinson disease: Isradipine, an L-type calcium channel blocker, demonstrates protective effects against α-synuclein, 6-hydroxydopamine (6-OHDA) or MPTP-induced neurotoxicity in DAergic neurons [29,30,31], supporting the association between calcium influx through L-type CA2+ channels and PD pathogenesis.